AU6220398A - Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity - Google Patents

Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity

Info

Publication number
AU6220398A
AU6220398A AU62203/98A AU6220398A AU6220398A AU 6220398 A AU6220398 A AU 6220398A AU 62203/98 A AU62203/98 A AU 62203/98A AU 6220398 A AU6220398 A AU 6220398A AU 6220398 A AU6220398 A AU 6220398A
Authority
AU
Australia
Prior art keywords
scarring
receptor
mediated activity
inhibiting interleukin
reducing fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU62203/98A
Inventor
Mark William James Ferguson
Sharon O'kane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Victoria University of Manchester
Original Assignee
Victoria University of Manchester
University of Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Victoria University of Manchester, University of Manchester filed Critical Victoria University of Manchester
Publication of AU6220398A publication Critical patent/AU6220398A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276Knock-out vertebrates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/248IL-6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/075Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU62203/98A 1997-02-13 1998-02-13 Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity Abandoned AU6220398A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9702944.1A GB9702944D0 (en) 1997-02-13 1997-02-13 Reducing fibrosis
GB9702944 1997-02-13
PCT/GB1998/000319 WO1998036061A2 (en) 1997-02-13 1998-02-13 Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity

Publications (1)

Publication Number Publication Date
AU6220398A true AU6220398A (en) 1998-09-08

Family

ID=10807559

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62203/98A Abandoned AU6220398A (en) 1997-02-13 1998-02-13 Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity

Country Status (3)

Country Link
AU (1) AU6220398A (en)
GB (1) GB9702944D0 (en)
WO (1) WO1998036061A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9818278D0 (en) * 1998-08-22 1998-10-14 Smith & Nephew Compositions
DK1129190T4 (en) 1998-11-13 2017-04-03 Immunex Corp Human TSLP DNA and polypeptides
ES2286128T3 (en) * 2000-06-30 2007-12-01 Zymogenetics, Inc. ZCYTO21 PROTEIN INTERFERRED TYPE.
DK1417231T3 (en) 2001-07-23 2013-07-22 Immunex Corp MODIFIED HUMAN THYMIC STROMAL LYMPHOPOIETIN
WO2004045507A2 (en) * 2002-11-15 2004-06-03 Centocor, Inc. Anti-angiogenic uses of il-6 antagonists
CA2539061A1 (en) * 2003-09-22 2005-03-31 Biovation Gmbh & Co. Kg Use of an antagonist of il-6 for treating il-6-mediated diseases
US20060171943A1 (en) * 2005-02-01 2006-08-03 Amgen Inc. Compositions and methods of treating fibrotic disorders
EP1941907B1 (en) 2005-10-14 2016-03-23 Fukuoka University Inhibitor of transplanted islet dysfunction in islet transplantation
KR101239051B1 (en) 2005-10-21 2013-03-04 추가이 세이야쿠 가부시키가이샤 Agents for treating cardiopathy
AR057582A1 (en) 2005-11-15 2007-12-05 Nat Hospital Organization AGENTS TO DELETE INDUCTION OF CYTOTOXIC T LYMPHOCYTES
CN101370521A (en) 2006-01-27 2009-02-18 学校法人庆应义塾 Remedy for disease associated with choroidal angiogenesis
CA2648644C (en) 2006-04-07 2016-01-05 Osaka University Muscle regeneration promoter
MX2009001110A (en) 2006-08-03 2009-05-11 Vaccinex Inc Anti-il-6 monoclonal antibodies and uses thereof.
CN101646459B (en) 2007-01-23 2014-02-12 国立大学法人信州大学 Chronic rejection inhibitor
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
WO2009148148A1 (en) 2008-06-05 2009-12-10 国立がんセンター総長が代表する日本国 Neuroinvasion inhibitor
HRP20221490T1 (en) 2010-05-28 2023-02-03 Chugai Seiyaku Kabushiki Kaisha Antitumor t cell response enhancer
WO2013106702A1 (en) 2012-01-13 2013-07-18 President And Fellows Of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
TW201829460A (en) 2016-12-16 2018-08-16 新加坡商新加坡保健服務私人有限公司 Il-11 antibodies
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
CA3070089A1 (en) * 2017-07-19 2019-01-24 Auckland Uniservices Limited Cytokine modulation
KR20200074160A (en) 2017-10-20 2020-06-24 가꼬우호우징 효고 이카다이가쿠 Pharmaceutical composition for inhibiting post-surgical adhesion containing anti-IL-6 receptor antibody
EP3801525A4 (en) 2018-06-08 2022-03-23 The General Hospital Corporation Inhibitors of prolyl-trna-synthetase
JP2022518251A (en) 2019-01-21 2022-03-14 シンガポール・ヘルス・サービシーズ・ピーティーイー・リミテッド Treatment of hepatotoxicity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8910891A (en) * 1990-11-20 1992-06-11 National Heart & Lung Institute, The Treatment of lung diseases
JP3525221B2 (en) * 1993-02-17 2004-05-10 味の素株式会社 Immunosuppressants
WO1994025036A1 (en) * 1993-04-30 1994-11-10 Chugai Seiyaku Kabushiki Kaisha Expression inhibitor containing antisense oligonucleotide derivative against human interleukin-6 receptor
RU2147442C1 (en) * 1994-10-21 2000-04-20 Кисимото Тадамицу Pharmaceutical composition for prophylaxis or treatment of diseases caused by il-6 formation
IT1274782B (en) * 1994-12-14 1997-07-24 Angeletti P Ist Richerche Bio METHOD FOR SELECTING SUPERAGONISTS, ANTAGONISTS AND SUPERANTAGONISTS OF HORMONES OF WHICH RECEPTOR COMPLEX IS PART OF GP 130
AU3193097A (en) * 1996-06-20 1998-01-07 Koster, Henk W. Il-6 and il-6-receptor derived peptides having il-6 antagonistic or agonistic activity

Also Published As

Publication number Publication date
GB9702944D0 (en) 1997-04-02
WO1998036061A2 (en) 1998-08-20
WO1998036061A3 (en) 1998-11-12

Similar Documents

Publication Publication Date Title
AU6220398A (en) Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity
AU6244098A (en) Distributed game
AU3741699A (en) Personal location system
AU4943200A (en) Modified cytokine
AU4723296A (en) Compositions having depigmenting activity, and uses thereof
AU1024899A (en) Cytokines having neurotrophic activity
AU3206697A (en) Ribozyme-mediated gene replacement
AU5203698A (en) Fluid-treatment assemblies
AU2321397A (en) Construction block structure
EP0903415A3 (en) Structure expansée
AU8165298A (en) Cardiotrophin-like cytokine
AU7474998A (en) Haloisoquinoline carboxamide
AU7020398A (en) Personal communications system
AU9367198A (en) Enzymatic modification
AU1365499A (en) Pre-orienting nozzle
AU6673898A (en) Factor x variant
AU3702399A (en) Catalytically active structure
AU6230398A (en) Thrombolytic agent
AU1873499A (en) Semi-submersible structure
AU8736698A (en) Shale-stabilizing additives
AU7308300A (en) Agents for reducing cholesterol-uptake and liquid-uptake
AU7162898A (en) Regioisomeric benzothiopyranopyridines having antitumor activity
AU8808098A (en) Bis-acridinecarboxamides having antitumor activity
AU7226598A (en) Stay
AU4414699A (en) Printhead attachment structure and method